A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

The discovery of the first mRNA-stabilizing substance could pave the way for groundbreaking advancements in the development ...

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid ...

Study reveals single-chain mRNA vaccines confer 100% protection against lethal mpox challenge in mice, marking a significant ...

A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...

In an era where viral outbreaks can escalate into global pandemics with alarming speed, the ability to quickly develop new ...

On Monday, Moderna Inc (MRNA) stock saw a decline, ending the day at $53.8 which represents a decrease of $-0.30 or -0.55% from the prior close of $54.1. The stock opened at $53.82 and touched a low ...

Researchers are developing what they hope will be the first successful vaccine against the highly contagious and difficult-to ...

Scientists in Australia have found why mRNA vaccines trigger side effects, paving the way for more effective vaccines.

Messenger RNA (mRNA) serves as a blueprint for proteins. When mRNA is no longer needed, it must be degraded. Director Elena ...

The trial will evaluate the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403 ...